KCM Investment Advisors LLC Purchases 279 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

KCM Investment Advisors LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 39,157 shares of the medical equipment provider’s stock after acquiring an additional 279 shares during the quarter. KCM Investment Advisors LLC’s holdings in Zimmer Biomet were worth $4,227,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. BLB&B Advisors LLC raised its holdings in Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after purchasing an additional 100 shares during the period. Financial Advocates Investment Management raised its holdings in Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares during the period. M&R Capital Management Inc. raised its holdings in Zimmer Biomet by 14.1% in the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 105 shares during the period. Mill Creek Capital Advisors LLC raised its holdings in Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 106 shares during the period. Finally, HB Wealth Management LLC raised its holdings in Zimmer Biomet by 2.8% in the 2nd quarter. HB Wealth Management LLC now owns 3,864 shares of the medical equipment provider’s stock worth $419,000 after purchasing an additional 107 shares during the period. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZBH. Royal Bank of Canada raised their target price on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Wells Fargo & Company raised their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Truist Financial increased their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research note on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Finally, BTIG Research cut their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Trading Up 0.9 %

ZBH traded up $0.96 on Friday, hitting $109.81. The company had a trading volume of 195,321 shares, compared to its average volume of 1,485,406. The company has a market cap of $21.86 billion, a PE ratio of 20.86, a PEG ratio of 2.02 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The business’s fifty day simple moving average is $106.13 and its 200 day simple moving average is $110.18.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.65 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.